This laboratory approach identifies peptides recovered with immune display molecules. It supplies evidence about peptide presentation in the material that was analyzed.
A primary melanoma study used mass spectrometry to identify HLA-associated peptides from native tumor tissue and then evaluated selected mutated peptides with immune assays. This is stronger evidence of natural presentation in the sampled material than a binding prediction alone. The analytical observation still has a defined specimen and workflow. It does not automatically establish the abundance of a ligand on every cancer cell, receptor recognition or a treatment effect. A published protocol isolates MHC-peptide complexes by immunoaffinity capture, dissociates the peptides by acid denaturation, fractionates them by HPLC and identifies them by nano-UPLC tandem mass spectrometry, from cell lines and tissues (Purcell and colleagues, 2019). Capture starts from mild-detergent solubilised lysates (Chong and colleagues, 2018; Sarkizova and colleagues, 2020 immunoprecipitated HLA from soluble lysates), so a lysate is not a surface-only survey, and in multi-allele samples a peptide was assigned to the best-scoring allele or alleles by computation (Sarkizova and colleagues, 2020). Identification depends on the analysis: a deep-learning model trained on more than 300,000 synthetic peptides improved HLA peptide identification up to 7-fold and indicated that 87 per cent of the proposed proteasomally spliced HLA peptides may be incorrect (Wilhelm and colleagues, 2021). A quantitative tissue study isolated peptide-HLA complexes from snap-frozen tissue and used formalin-fixed paraffin-embedded blocks only for histology (Science Translational Medicine, 2022).
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen, Antigen presentation & immune editing.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen, Antigen presentation & immune editing.
Shares Finite tissue and specimen allocation, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Finite tissue and specimen allocation, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/